Please login to the form below

Not currently logged in
Email:
Password:

Novimmune appoints Guillaume de Sampaïo

He brings experience from Roche, Novartis and Actelion to the Swiss biotech 

Swiss biotech Novimmune has appointed Guillaume de Sampaïo as global head of project management in a role that will also see him sit on its senior management team.

De Sampaïo has 15 years experience in life sciences, having previously served at the likes of Roche, Novartis and Actelion.

Prior to joining Novimmune he served at Danish biotech firm Forward Pharma, where he created and managed its clinical development group.

During that time he contributed to the development of the company's clinical trial portfolio and the facilitation of its successful US IPO during 2014. 

Novimmune chairman and CEO Eduard Holdener said: “With the progression of our R&D pipeline, project management becomes increasingly a crucial element in supporting our growth strategy. 

“Guillaume de Sampaïo will help us to further advance Novimmune as we move closer to the market with our lead program, NI-0501.”

30th November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics